PMID- 22822651
OWN - NLM
STAT- MEDLINE
DCOM- 20120920
LR  - 20181201
IS  - 0300-5283 (Print)
IS  - 0300-5283 (Linking)
VI  - 67
IP  - 2
DP  - 2012 Apr
TI  - Cutaneous side-effects of epidermal growth factor receptor-tyrosine kinase 
      inhibitor (TKI) in the treatment of lung cancer: description and its management.
PG  - 222-3
AB  - Epidermal growth factor receptor (EGFR)--tyrosine kinase inhibitors (TKI) like 
      erlotinib and gefitinib have been approved as monotherapy for the treatment of 
      patients with locally advanced or metastatic non small cell lung cancer (NSCLC) 
      after failure of at least one prior chemotherapy regimen. The use of EGFR-TKI is 
      associated with unique and dramatic dermatologic side effects. We report 2 
      patients with NSCLC developing a typical acneiform (papulo-pustular) eruption 
      shortly after initiation of EGFR-TKI.
FAU - Ong, C K
AU  - Ong CK
AD  - Department of Respiratory Medicine, Hospital Pulau Pinang, Penang, Malaysia. 
      ongchookhoon@yahoo.com
FAU - Tan, W C
AU  - Tan WC
FAU - Chan, L C
AU  - Chan LC
FAU - Abdul Razak, M
AU  - Abdul Razak M
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - Malaysia
TA  - Med J Malaysia
JT  - The Medical journal of Malaysia
JID - 0361547
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Quinazolines)
RN  - DA87705X9K (Erlotinib Hydrochloride)
RN  - S65743JHBS (Gefitinib)
SB  - IM
MH  - Adenocarcinoma/*drug therapy
MH  - Adult
MH  - Disease Progression
MH  - Drug Eruptions/*drug therapy
MH  - Erlotinib Hydrochloride
MH  - Female
MH  - Gefitinib
MH  - Humans
MH  - Lung Neoplasms/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Protein Kinase Inhibitors/*adverse effects
MH  - Quinazolines/*adverse effects
EDAT- 2012/07/25 06:00
MHDA- 2012/09/21 06:00
CRDT- 2012/07/25 06:00
PHST- 2012/07/25 06:00 [entrez]
PHST- 2012/07/25 06:00 [pubmed]
PHST- 2012/09/21 06:00 [medline]
PST - ppublish
SO  - Med J Malaysia. 2012 Apr;67(2):222-3.